These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19101363)

  • 1. [Antipsychotic agents: what do meta analyses say?].
    Millet B
    Encephale; 2007 Jun; 33 Pt 3():S419-24. PubMed ID: 19101363
    [No Abstract]   [Full Text] [Related]  

  • 2. [Atypical neuroleptics--a heterogenous group. Valuable option in acute psychoses].
    MMW Fortschr Med; 2002 May; Suppl 2():85. PubMed ID: 12070863
    [No Abstract]   [Full Text] [Related]  

  • 3. Cognitive behavior therapy for schizophrenia: a meta-analytical review of randomized controlled trials.
    Sarin F; Wallin L; Widerlöv B
    Nord J Psychiatry; 2011 Jun; 65(3):162-74. PubMed ID: 21563994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Poker ala the "mega" studies].
    Kálmán J
    Neuropsychopharmacol Hung; 2008 Dec; 10(5):261-2. PubMed ID: 19419010
    [No Abstract]   [Full Text] [Related]  

  • 5. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 6. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological treatment of schizophrenia.
    Leucht S; Heres S; Kissling W; Davis JM
    Fortschr Neurol Psychiatr; 2013 May; 81(5):e1-13. PubMed ID: 23702802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schizophrenia: recent advances in psychopharmacology.
    Sharma T
    Br J Hosp Med; 1996 Feb 21-Mar 5; 55(4):194-8. PubMed ID: 8777500
    [No Abstract]   [Full Text] [Related]  

  • 9. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apomorphine's antipsychotic activity.
    Schaffer MH; Davis JM; Tamminga CA
    Arch Gen Psychiatry; 1985 Sep; 42(9):927-8. PubMed ID: 2864035
    [No Abstract]   [Full Text] [Related]  

  • 11. Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.
    Taylor DM; Smith L
    Acta Psychiatr Scand; 2009 Jun; 119(6):419-25. PubMed ID: 19245679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses.
    Tandon R; Nasrallah HA
    Arch Gen Psychiatry; 2006 Aug; 63(8):935-7; author reply 937-9. PubMed ID: 16894070
    [No Abstract]   [Full Text] [Related]  

  • 13. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended.
    Leucht S; Busch R; Hamann J; Kissling W; Kane JM
    Biol Psychiatry; 2005 Jun; 57(12):1543-9. PubMed ID: 15953491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placebo or active control trials of antipsychotic drugs?
    Fleischhacker WW; Czobor P; Hummer M; Kemmler G; Kohnen R; Volavka J
    Arch Gen Psychiatry; 2003 May; 60(5):458-64. PubMed ID: 12742866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementing treatment guidelines.
    Miller AL
    Clin Schizophr Relat Psychoses; 2011 Apr; 5(1):15-6. PubMed ID: 21459734
    [No Abstract]   [Full Text] [Related]  

  • 16. Atypical antipsychotic medications and the treatment of schizophrenia.
    Lewis DA
    Am J Psychiatry; 2002 Feb; 159(2):177-9. PubMed ID: 11823256
    [No Abstract]   [Full Text] [Related]  

  • 17. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
    Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW
    Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression.
    Welge JA; Keck PE
    Psychopharmacology (Berl); 2003 Feb; 166(1):1-10. PubMed ID: 12494247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ICI 204,636: a new atypical antipsychotic drug.
    Hirsch SR; Link CG; Goldstein JM; Arvanitis LA
    Br J Psychiatry Suppl; 1996 May; (29):45-56. PubMed ID: 8733823
    [No Abstract]   [Full Text] [Related]  

  • 20. Heterogeneity of treatment effects in schizophrenia.
    Stroup TS
    Am J Med; 2007 Apr; 120(4 Suppl 1):S26-31. PubMed ID: 17403379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.